Companies could see the time it takes to register their new drugs in Saudi Arabia drop from around 290 days to just 30 days, thanks to a new abridged review mechanism that goes live in February. The development means that swifter access in nearby markets could be next if other regional regulators follow suit, says Paul Dearden, AbbVie Inc.'s head of emerging markets, regulatory policy & intelligence.
The Saudi Food & Drug Authority says it has adopted a new mechanism for abridging drug registrations which will be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?